S&P 500
(1.02%) 5 099.96 points
Dow Jones
(0.40%) 38 240 points
Nasdaq
(2.03%) 15 928 points
Oil
(0.11%) $83.66
Gas
(-1.16%) $1.619
Gold
(0.30%) $2 349.60
Silver
(-0.43%) $27.52
Platinum
(0.42%) $924.40
USD/EUR
(0.32%) $0.935
USD/NOK
(0.67%) $11.02
USD/GBP
(0.13%) $0.800
USD/RUB
(-0.07%) $92.11

Sanntidsoppdatering for Bavarian Nordic A/S [BVNRY]

Børs: OTC Sektor: Healthcare Industri: Biotechnology
Sist oppdatert26 apr 2024 @ 17:20

1.82% $ 7.05

Live Chart Being Loaded With Signals

Commentary (26 apr 2024 @ 17:20):

Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name...

Stats
Dagens volum 892.00
Gjennomsnittsvolum 5 243.00
Markedsverdi 1.65B
EPS $0 ( 2024-03-07 )
Neste inntjeningsdato ( $0 ) 2024-05-14
Last Dividend $0.593 ( 2020-03-27 )
Next Dividend $0 ( N/A )
P/E 7.66
ATR14 $0 (0.00%)

Bavarian Nordic A/S Korrelasjon

10 Mest positive korrelasjoner
10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Bavarian Nordic A/S Økonomi

Annual 2023
Omsetning: $7.06B
Bruttogevinst: $4.52B (64.07 %)
EPS: $19.23
FY 2023
Omsetning: $7.06B
Bruttogevinst: $4.52B (64.07 %)
EPS: $19.23
FY 2023
Omsetning: $0
Bruttogevinst: $0 (0.00 %)
EPS: $0
FY 2022
Omsetning: $3.15B
Bruttogevinst: $1.70B (53.99 %)
EPS: $-4.93

Financial Reports:

No articles found.

Bavarian Nordic A/S Dividends

(Q3/22) (Q4/22) (Q1/23) (Q2/23) (Q3/23) (Q4/23) (Q1/24) (Q2/24) (Q3/24) (Q4/24)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)

Bavarian Nordic A/S Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 4.34 - Potential for dividend initiation, but uncertain (13.19%)
Information
First Dividend $0.593 2020-03-27
Last Dividend $0.593 2020-03-27
Next Dividend $0 N/A
Payout Date 2020-04-06
Next Payout Date N/A
# dividends 1 --
Total Paid Out $0.593 --
Avg. Dividend % Per Year 0.00% --
Score 2.27 --
Div. Sustainability Score 10.00
Div.Growth Potential Score 4.34
Div. Directional Score 7.53 --
Next Divdend (Est)
(2024-04-28)
$0 Estimate 0.00 %
Dividend Stability
0.02 Very Bad
Dividend Score
2.27
Pay Frequency
Insufficient data to determine frequency
Yearly Payout
Year Amount Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for OTC

Symbol Title Last dividend Frequency Years Dividend Yearly Dividend Score
TISCF Ex Dividend Junior 2023-09-28 Annually 0 0.00%
IKTSY Ex Dividend Knight 2023-09-14 Semi-Annually 0 0.00%
BHRB Ex Dividend Knight 2023-08-14 Quarterly 0 0.00%
PRNDY Ex Dividend Knight 2023-06-30 Semi-Annually 0 0.00%
EMSHF Ex Dividend Knight 2023-08-15 Annually 0 0.00%
UNCHF Ex Dividend Knight 2023-12-28 Semi-Annually 0 0.00%
KIROY Ex Dividend Knight 2023-08-17 Semi-Annually 0 0.00%
CCFN Ex Dividend Knight 2023-08-14 Quarterly 0 0.00%
SBGSY Ex Dividend Knight 2023-05-09 Annually 0 0.00%
FOJCY Ex Dividend Junior 2023-09-29 Annually 0 0.00%

Dividend Sustainability Score (DSS)

RatioActual ValueWeightNormalized ValueScoreRange
netProfitMarginTTM0.2091.5005.828.74[0 - 0.5]
returnOnAssetsTTM0.1031.2006.577.89[0 - 0.3]
returnOnEquityTTM0.1531.5009.4110.00[0.1 - 1]
payoutRatioTTM0-1.00000[0 - 1]
currentRatioTTM1.9380.8005.314.25[1 - 3]
quickRatioTTM1.3420.8006.815.45[0.8 - 2.5]
cashRatioTTM0.5301.5008.1710.00[0.2 - 2]
debtRatioTTM0.00430-1.5009.93-10.00[0 - 0.6]
interestCoverageTTM25.161.0001.7931.793[3 - 30]
operatingCashFlowPerShareTTM14.592.005.1410.00[0 - 30]
freeCashFlowPerShareTTM1.8492.009.0810.00[0 - 20]
debtEquityRatioTTM0.00597-1.5009.98-10.00[0 - 2.5]
grossProfitMarginTTM0.6521.0002.472.47[0.2 - 0.8]
operatingProfitMarginTTM0.2151.0007.707.70[0.1 - 0.6]
cashFlowToDebtRatioTTM18.151.00010.0010.00[0.2 - 2]
assetTurnoverTTM0.4920.800-0.0521-0.0416[0.5 - 2]
Total Score10.72

Dividend Growth Score (DGS)

RatioActual ValueWeightNormalized ValueScoreRange
peRatioTTM2.551.0009.840[1 - 100]
returnOnEquityTTM0.1532.509.6210.00[0.1 - 1.5]
freeCashFlowPerShareTTM1.8492.009.3810.00[0 - 30]
dividendYielPercentageTTM01.50000[0 - 0.4]
operatingCashFlowPerShareTTM14.592.005.1410.00[0 - 30]
payoutRatioTTM01.50000[0 - 1]
pegRatioTTM0.002281.500-3.320[0.5 - 2]
operatingCashFlowSalesRatioTTM0.1581.0008.540[0.1 - 0.5]
Total Score4.34

Bavarian Nordic A/S

Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name. It is also developing MVA-BN (freeze-dried) that has completed Phase III clinical trials for the treatment of smallpox; MVA-BN RSV, which is in Phase III clinical trials for the treatment of respiratory syncytial virus; ABNCoV2 that has completed Phase II clinical trial for the treatment of SARS-CoV-2; and TAEK-VAC, which is in Phase I/II clinical trial for treatment of advanced HER2 and brachyury-expressing cancers. It has license and collaboration agreement with AdaptVac; and license agreements with National Cancer Institute and Public Health Service. The company operates in the United States, Belgium, Germany, the Netherlands, Sweden, Switzerland, Austria, the United Kingdom, Japan, and internationally. Bavarian Nordic A/S was incorporated in 1992 and is headquartered in Hellerup, Denmark.

Om Live Signaler

Live Trading signaler pa denne siden er ment til å hjelpe deg i beslutningsprossessen for når du bør KJØPE eller SELGE NA. Signalene har opp mot 1-minutt forsinkelse; som med alle andre indikatorer og signaler, er det en viss sjanse for feil eller feilkalkuleringer.

Live signalene er kun veiledende, og getagraph.com tar ikke noen form for ansvar basert pa handlinger gjort på disse signalene som beskrevet i Terms of Use. Signalene er basert på en rekke indikatorer og påliteligheten vil variere sterke fra aksje til aksje.